{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:28:12Z","timestamp":1792859292018,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtho.2024.12.027","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T03:01:14Z","timestamp":1735786874000},"page":"665-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN\/TORG2040)"],"prefix":"10.1016","volume":"20","author":[{"given":"Tomoya","family":"Fukui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Masubuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiichiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Naoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.027_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008-2030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","article-title":"Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience","volume":"9","author":"Albain","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","article-title":"Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party","volume":"13","author":"Paesmans","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib4","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib7","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","article-title":"Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2","volume":"31","author":"Zukin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib11","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)","volume":"12","author":"Iwama","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.027_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2024.12.027_bib16","doi-asserted-by":"crossref","first-page":"23874","DOI":"10.18632\/oncotarget.8074","article-title":"Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.12.027_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyz041","article-title":"Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status","volume":"49","author":"Nakashima","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib20","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.21037\/jtd.2019.06.03","article-title":"Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"11","author":"Kato","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2024.12.027_bib21","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s10637-020-00943-0","article-title":"Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial","volume":"38","author":"Nakashima","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2024.12.027_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","article-title":"Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)","volume":"27","author":"Tsubata","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","article-title":"First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: a prospective observational study","volume":"40","author":"Igawa","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2024.12.027_bib24","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1111\/1759-7714.14608","article-title":"Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib","volume":"13","author":"Teranishi","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib25","doi-asserted-by":"crossref","first-page":"87-e115","DOI":"10.1002\/onco.13951","article-title":"First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study","volume":"27","author":"Lorenzi","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.12.027_bib26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1186\/s12885-022-10409-6","article-title":"Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN\/TORG2040)","volume":"22","author":"Fukui","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bjc.6603710","article-title":"Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib","volume":"96","author":"Satouchi","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib28","first-page":"5057","article-title":"Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status","volume":"33","author":"Okuma","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2024.12.027_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-022-09741-8","article-title":"Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis","volume":"22","author":"Gen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02561-z","article-title":"First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)","volume":"11","author":"Yamamoto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.027_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/1759-7714.14782","article-title":"TAPO in first-line osimertinib therapy and continuation of osimertinib","volume":"14","author":"Mimura","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib36","article-title":"Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial","volume":"190","author":"Connor","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.027_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2024.12.027_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1617","article-title":"Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis","volume":"3","author":"Erickson","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2024.12.027_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to Osimertinib versus Standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib42","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.027_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.027_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","article-title":"Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC","volume":"16","author":"Lamb","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtho.2024.12.027_bib45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2024.12.027_bib46","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.027_bib47","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:37:14Z","timestamp":1777639034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1556086424025486"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.027","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN\/TORG2040)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}